KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Receivables (2016 - 2025)

Historic Receivables for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $14.3 billion.

  • Pfizer's Receivables fell 132.17% to $14.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $14.3 billion, marking a year-over-year decrease of 132.17%. This contributed to the annual value of $11.5 billion for FY2024, which is 89.05% down from last year.
  • According to the latest figures from Q3 2025, Pfizer's Receivables is $14.3 billion, which was down 132.17% from $12.1 billion recorded in Q2 2025.
  • Pfizer's Receivables' 5-year high stood at $16.2 billion during Q4 2022, with a 5-year trough of $10.2 billion in Q3 2023.
  • Moreover, its 5-year median value for Receivables was $11.6 billion (2023), whereas its average is $12.3 billion.
  • Per our database at Business Quant, Pfizer's Receivables skyrocketed by 3997.82% in 2022 and then plummeted by 3368.12% in 2023.
  • Quarter analysis of 5 years shows Pfizer's Receivables stood at $11.5 billion in 2021, then fell by 5.03% to $11.0 billion in 2022, then increased by 5.61% to $11.6 billion in 2023, then fell by 0.89% to $11.5 billion in 2024, then grew by 24.4% to $14.3 billion in 2025.
  • Its Receivables was $14.3 billion in Q3 2025, compared to $12.1 billion in Q2 2025 and $11.8 billion in Q1 2025.